|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Multicenter, Double Blind, Comparative Study of the Efficacy and Safety of Terbinafine 250mg/day for 4 weeks in the Treatment of Patients with Tinea Pedis |
| Ki-Hong Kim1, Jong Soo Choi1, Eui Soo Park2, Sang-Won Kim3, Soo Chan Kim4, Sung Gu Ahn5, Moo Kyu Suh6, Soon Bong Suh7 |
| Department of Dermatology, College of Mecicine, Yeungnam University1, Keimyung University2, Taegu Catholic University3, Yonsei University4, Wonju Christian Hospital Yonsei University5, DongKook University6, Catholic Skin Clinic7 |
Vol.12 Num.2 (p162~172)
|
|
|
In this randomized double-blind trial on multicenter study, the efficacy of the new antifungal agent, terbinafine was compared with the triazole antifungal agent, itraconazole, in the treatment of patients with various froms of tinea pedis.
One hundred and ten patients(55 terbinafine, 55 itraconazole) with tinea pedis were enrolled. Eleven patients were lost to follow-up(5 terbinafine, 8 itraconazole) and 9 reported adverse reaction with premature discontinuation of therapy.
And 90 patients were eligible for follow-up until 6 weeks after starting the treatment. Forty six patients received terbinafine 250mg daily for two weeks and 44 received intraconazole 100mg daily for 4 weeks. They were checked clinical symptoms and mycological improvement with KOH wet mount and culture during the study.
Clinical and mycological cure rate of the terbinafine group was 6.5% at 1 week after intial treatment, 23.9% at 2 weeks, 69.6% at 4 weeks and 89.1% at 6 weeks and that of the itraconazole group was 0% at 1 week after intial treatment, 22.7% at 2 weeks, 59.1% at 4 weeks, and 77.3% at 6 weeks. Adverse reactions and tolerability of both drugs were not different significantly.
All these findings suggest that the effects of terbinafine 250mg daily for 2 weeks in the treatment of tinea pedis was similar to that of intraconazole 100mg daily for 4 weeks.
|
|
|
Keywords : |
|
|
|
|
|
|
|
|
